Inventiva Completes Final 72-Week NATiV3 Patient Visit With 1,419 Patients Enrolled, Topline Results Expected Q4 2026
Last patient completed final 72-week visit in NATiV3, with 1,009 patients enrolled in the main cohort and 410 patients in the exploratory cohortTopline results of NATiV3 expected in Q4 2026September investor conference
Read original at benzinga